Lack of KRAS Gene Mutations in Chronic Myeloid Leukemia in Iran |
Kooshyar, Mohammad Mahdi
(Hematology Department, Cancer Molecular Pathology Research Center)
Ayatollahi, Hossein (Hematopathology Department, Cancer Molecular Pathology Research Center) Keramati, Mohammad Reza (Hematopathology Department, Cancer Molecular Pathology Research Center) Sadeghian, Mohammad Hadi (Hematopathology Department, Cancer Molecular Pathology Research Center) Miri, Mohsen (Faculty of Medicine, Mashhad University of Medical Sciences) Sheikhi, Maryam (Faculty of Medicine, Mashhad University of Medical Sciences) |
1 | Ahuja HG, Foti A, Bar-Eli M, Cline MJ (1990). The pattern of mutational involvement of RAS genes in human hematologic malignancies determined by DNA amplification and direct sequencing. Blood, 75, 1684-90. |
2 | Bain BG, Clark DM, Wilkins BS (2010). Myeloprolifrative and myelodysplastic/Myeloprolifrative neoplasms and related conditions. In: Bain BG, Clark DM, Wilkins BS, editors. Bone marrrow pathology. 4th ed: Wiley-Blackwell, 240-2. |
3 | Baum KJ, Ren R (2008). Effect of Ras inhibition in hematopoiesis and BCR/ABL leukemogenesis. J Hematol Oncol, 1, 5. DOI ScienceOn |
4 | Braun BS, Shannon K (2008). Targeting Ras in myeloid leukemias. Clin Cancer Res, 14, 2249-52. DOI ScienceOn |
5 | Braun BS, Tuveson DA, Kong N, et al (2004). Somatic activation of oncogenic Kras in hematopoietic cells initiates a rapidly fatal myeloproliferative disorder. Proc Natl Acad Sci USA, 101, 597-602. DOI ScienceOn |
6 | Chan IT, Kutok JL, Williams IR, et al (2004). Conditional expression of oncogenic K-ras from its endogenous promoter induces a myeloproliferative disease. J Clin Invest, 113, 528-38. DOI ScienceOn |
7 | LeMaistre A, Lee MS, Talpaz M, et al (1989). Ras oncogene mutations are rare late stage events in chronic myelogenous leukemia. Blood, 73, 889-91. |
8 | Liang DC, Shih LY, Fu JF, et al (2006). K-Ras mutations and N-Ras mutations in childhood acute leukemias with or without mixed-lineage leukemia gene rearrangements. Cancer, 106, 950-6. DOI ScienceOn |
9 | Mansi L, Viel E, Curtit E, Medioni J, Le Tourneau C (2011). Targeting the RAS signalling pathway in cancer. Bulletin Du Cancer, 98, 1019-28. |
10 | McCubrey JA, Steelman LS, Abrams SL, et al (2008). Targeting survival cascades induced by activation of Ras/Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR and Jak/STAT pathways for effective leukemia therapy. Leukemia, 22, 708-22. DOI ScienceOn |
11 | Nagasaka T, Sasamoto H, Notohara K, et al (2004). Colorectal cancer with mutation in BRAF, KRAS, and wild-type with respect to both oncogenes showing different patterns of DNA methylation. J Clin Oncol, 22, 4584-94. DOI ScienceOn |
12 | Needleman SW, Gutheil JC, Kapil V, Mane SM (1989). Infrequent ras activation in chronic myelogenous leukemia (CML): Activating 61st codon mutation in the CML-derived cell line, IM-9. Leukemia, 3, 827-9. |
13 | Pavlu J, Andreasson C, Chuah C, et al (2007). Dual inhibition of ras and bcr-abl signalling pathways in chronic myeloid leukaemia: a phase I/II study in patients in complete haematological remission. Bri J Haematol, 137, 423-8. DOI ScienceOn |
14 | Preston R, Dabritz J, Hanfler J, Oettle H (2010). Mutational analysis of K-ras codon 12 in blood samples of patients with acute myeloid leukemia. Leukemia Res, 34, 883-91. DOI ScienceOn |
15 | Sano H, Shimada A, Taki T, et al (2012). RAS mutations are frequent in FAB type M4 and M5 of acute myeloid leukemia, and related to late relapse: a study of the Japanese childhood AML cooperative study group. Int J Hematol, 95, 509-15. DOI ScienceOn |
16 | Serra A, Guerrasio A, Gaidano G, et al (1993). molecular defects associated with the acute-phase CML. Leukemia Lymphoma, 11, 25-8. |
17 | Steelman LS, Franklin RA, Abrams SL, et al (2011). Roles of the Ras/Raf/MEK/ERK pathway in leukemia therapy. Leukemia, 25, 1080-94. DOI ScienceOn |
18 | Stoppa G, Rumiato E, Saggioro D. (2012) Ras signaling contributes to survival of human T-cell leukemia/lymphoma virus type 1 (HTLV-1) Tax-positive T-cells. Apoptosis, 17, 219-28. DOI |
19 | Stricker TP, Kumar V (2012). In: Kumar V, Abbas AK, Fausto N, Aster JC, editors (2012). Robbins and Cotran Pathologic Basis of Disease. 8th ed. Philadelphia: Saunders Elsevier, 259-320. |
20 | Tyner JW, Erickson H, Deininger MW, et al (2009). High-throughput sequencing screen reveals novel, transforming RAS mutations in myeloid leukemia patients. Blood, 113, 1749-55. DOI ScienceOn |
21 | Watzinger F, Gaiger A, Karlic H, et al (1994). Absence of n-ras mutations in myeloid and lymphoid blast crisis of chronic myeloid-leukemia. Cancer Res, 54, 3934-8. |
22 | Zhu X, Li Y, Luo X, Fei J (2012). Inhibition of small GTPase RalA regulates growth and arsenic-induced apoptosis in chronic myeloid leukemia (CML) cells. Cellular Signalling, 24, 1134-40. DOI ScienceOn |